Novel treatment regimen of Vogt–Koyanagi–Harada disease with a reduced dose of corticosteroids combined with immunosuppressive agents

References

• Yang P, Ren Y, Li B, Fang W, Meng Q, Kijlstra A. Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients. Ophthalmology. 2007;114(3):606–14. doi:10.1016/j.ophtha.2006.07.040.
   PubMed Web of Science ®Google Scholar
• Moorthy RS, Inomata H, Rao NA. Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol. 1995;39(4):265–92. doi:10.1016/S0039-6257(05)80105-5.
   PubMed Web of Science ®Google Scholar
• Damico FM, Kiss S, Young LH. Vogt-Koyanagi-Harada disease. Semin Ophthalmol. 2005;20(3):183–90. doi:10.1080/08820530500232126.
   PubMedGoogle Scholar
• Read RW, Yu F, Accorinti M, Bodaghi B, Chee SP, Fardeau C, Goto H, Holland GN, Kawashima H, Kojima E, et al. Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2006;142(1):119–24. doi:10.1016/j.ajo.2006.02.049.
   PubMed Web of Science ®Google Scholar
• Keino H, Goto H, Mori H, Iwasaki T, Usui M. Association between severity of inflammation in CNS and development of sunset glow fundus in Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2006;141(6):1140–42. doi:10.1016/j.ajo.2006.01.017.
   PubMed Web of Science ®Google Scholar
• Lai TY, Chan RP, Chan CK, Lam DS. Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada disease. Eye (Lond). 2009;23(3):543–48. doi:10.1038/eye.2008.89.
   PubMed Web of Science ®Google Scholar
• Sakata VM, Da Silva FT, Hirata CE, Marin ML, Rodrigues H, Kalil J, Costa RA, Yamamoto JH. High rate of clinical recurrence in patients with Vogt-Koyanagi-Harada disease treated with early high-dose corticosteroids. Graefes Arch Clin Exp Ophthalmol. 2015;253(5):785–90. doi:10.1007/s00417-014-2904-z.
   PubMed Web of Science ®Google Scholar
• Chee SP, Jap A, Bacsal K. Spectrum of Vogt-Koyanagi-Harada disease in Singapore. Int Ophthalmol. 2007;27(2–3):137–42. doi:10.1007/s10792-006-9009-6.
   PubMedGoogle Scholar
• Keino H, Goto H, Usui M. Sunset glow fundus in Vogt-Koyanagi-Harada disease with or without chronic ocular inflammation. Graefes Arch Clin Exp Ophthalmol. 2002;240(10):878–82. doi:10.1007/s00417-002-0538-z.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Yu HG. The use of low-dose azathioprine in patients with Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm. 2007;15(5):381–87. doi:10.1080/09273940701624312.
   PubMed Web of Science ®Google Scholar
• Rao NA. Treatment of Vogt-Koyanagi-Harada disease by corticosteroids and immunosuppressive agents. Ocul Immunol Inflamm. 2006;14(2):71–72. doi:10.1080/09273940600674368.
   PubMed Web of Science ®Google Scholar
• Andreoli CM, Foster CS. Vogt-Koyanagi-Harada disease. Int Ophthalmol Clin. 2006;46(2):111–22. doi:10.1097/00004397-200604620-00011.
   PubMedGoogle Scholar
• Hayasaka S, Okabe H, Takahashi J. Systemic corticosteroid treatment in Vogt-Koyanagi-Harada disease. Graefes Arch Clin Exp Ophthalmol. 1982;218(1):9–13. doi:10.1007/BF02134092.
   PubMed Web of Science ®Google Scholar
• Rubsamen PE, Gass JD. Vogt-Koyanagi-Harada syndrome. Clinical course, therapy, and long-term visual outcome. Arch Ophthalmol. 1991;109(5):682–87. doi:10.1001/archopht.1991.01080050096037.
   PubMedGoogle Scholar
• Herbort CP, Jr., Abu El Asrar AM, Yamamoto JH, Pavesio CE, Gupta V, Khairallah M, Tugal-Tutkun I, Soheilian M, Takeuchi M, Papadia M. Reappraisal of the management of Vogt-Koyanagi-Harada disease: sunset glow fundus is no more a fatality. Int Ophthalmol. 2016. doi:10.1007/s10792-016-0395-0.
   Web of Science ®Google Scholar
• Bordaberry MF. Vogt-Koyanagi-Harada disease: diagnosis and treatments update. Curr Opin Ophthalmol. 2010;21(6):430–35. doi:10.1097/ICU.0b013e32833eb78c.
   PubMed Web of Science ®Google Scholar
• Kawaguchi T, Horie S, Bouchenaki N, Ohno-Matsui K, Mochizuki M, Herbort CP. Suboptimal therapy controls clinically apparent disease but not subclinical progression of Vogt-Koyanagi-Harada disease. Int Ophthalmol. 2010;30(1):41–50. doi:10.1007/s10792-008-9288-1.
   PubMedGoogle Scholar
• Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arellanes-Garcia L, Pivetti-Pezzi P, Tessler HH, Usui M. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001;131(5):647–52. doi:10.1016/S0002-9394(01)00925-4.
   PubMed Web of Science ®Google Scholar
• Du L, Kijlstra A, Yang P. Vogt-Koyanagi-Harada disease: novel insights into pathophysiology, diagnosis and treatment. Prog Retin Eye Res. 2016;52:84–111. doi:10.1016/j.preteyeres.2016.02.002.
   PubMed Web of Science ®Google Scholar
• Lightman S. New therapeutic options in uveitis. Eye (Lond). 1997;11(Pt 2):222–26. doi:10.1038/eye.1997.56.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Al Tamimi M, Hemachandran S, Al-Mezaine HS, Al-Muammar A, Kangave D. Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroids. Acta Ophthalmol. 2013;91(6):e486–93. doi:10.1111/aos.12127.
   PubMed Web of Science ®Google Scholar
• Chee SP, Jap A, Bacsal K. Prognostic factors of Vogt-Koyanagi-Harada disease in Singapore. Am J Ophthalmol. 2009;147(1):154–61 e1. doi:10.1016/j.ajo.2008.07.044.
   PubMed Web of Science ®Google Scholar
• Ozdal P, Ozdamar Y, Yazici A, Teke MY, Ozturk F. Vogt-Koyanagi-Harada disease: clinical and demographic characteristics of patients in a specialized eye hospital in Turkey. Ocul Immunol Inflamm. 2014;22(4):277–86. doi:10.3109/09273948.2013.856448.
   PubMed Web of Science ®Google Scholar
• Murthy SI, Moreker MR, Sangwan VS, Khanna RC, Tejwani S. The spectrum of Vogt-Koyanagi-Harada disease in South India. Int Ophthalmol. 2007;27(2–3):131–36. doi:10.1007/s10792-007-9046-9.
   PubMedGoogle Scholar
• Yang P, Fang W, Meng Q, Ren Y, Xing L, Kijlstra A. Clinical features of chinese patients with Behcet’s disease. Ophthalmology. 2008;115(2):312–8 e4. doi:10.1016/j.ophtha.2007.04.056.
   PubMed Web of Science ®Google Scholar
• Read RW, Rechodouni A, Butani N, Johnston R, LaBree LD, Smith RE, Rao NA. Complications and prognostic factors in Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2001;131(5):599–606. doi:10.1016/S0002-9394(01)00937-0.
   PubMed Web of Science ®Google Scholar